- Trial phase
- Approved
- Time to market
- Already on the market since 1999 (original) and 2014 (RT formulation).
- Why 3/10
- NovoSeven is an already-approved, marketed drug with no pending PDUFA date, pivotal readout, or Advisory Committee meeting scheduled in the next ~12 months. The only active clinical program is a small Phase 4 post-marketing safety study in India for postpartum hemorrhage, which is not a registrational catalyst. NovoSeven is a minor product within Novo Nordisk's rare disease segment (roughly 6% of total company revenue), which itself is dwarfed by the GLP-1 franchise. With no binary catalyst on the horizon, the impact score is capped at 3.
NovoSeven has no near-term binary catalyst. The Phase 4 postpartum hemorrhage safety study in India (NCT07157423) is still recruiting with no announced readout date. For Novo Nordisk investors, the drug is a mature, low-growth asset within a tiny segment of the business. The key drivers for NVO remain the GLP-1 franchise (Ozempic, Wegovy) and pipeline assets like oral semaglutide and CagriSema, not NovoSeven.
Price Chart
Executive Summary
NovoSeven (eptacog alfa) is an FDA-approved recombinant clotting factor marketed by Novo Nordisk since 1999 for treating bleeding episodes in hemophilia patients with inhibitors and other rare bleeding disorders. It is a mature, commercialized product facing growing competition from SevenFact (eptacog beta) and potential future biosimilars. For a Novo Nordisk investor, NovoSeven is a very small piece of the story: the company's rare disease segment contributed roughly 6% of 2025 revenue, and NovoSeven is just one product within that segment. The GLP-1 diabetes/obesity franchise (Ozempic, Wegovy) dominates the investment thesis. There are no near-term binary catalysts for this drug.
How It Works
NovoSeven is a lab-made version of a natural blood-clotting protein called Factor VIIa. When injected, it helps blood clot by bypassing the missing or blocked clotting factors (VIII and IX) that cause bleeding in hemophilia patients. It works only at the site of an injury, triggering a cascade that forms a clot and stops bleeding.
Trial Status
NovoSeven was first FDA-approved in 1999. The room-temperature-stable formulation (NovoSeven RT) was approved in 2014. It is a marketed product with approved indications for hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann's thrombasthenia, and acquired hemophilia. A Phase 4 post-marketing safety study (NCT07157423) is recruiting in India to evaluate safety in severe postpartum hemorrhage, with 64 patients targeted across 14 sites, last updated September 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 4 postpartum hemorrhage safety study (NCT07157423) in India, still recruiting, no topline readout date announced
- Potential biosimilar competition as patents expire
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVO NORDISK A S 6-K NVO ·Originating report